DarioHealth Expands Global Presence With Direct-to-Consumer Launch in the U.K.
DarioHealth opens new doors for U.K. consumers to personalize diabetes management with its strengthened commitment to the region
Apr 26, 2017
CAESAREA, Israel, April 26, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced the launch of a direct-to-consumer channel in the United Kingdom. Following the success of the direct-to-consumer channels in the U.S. and Australia, DarioHealth will leverage its knowledge to provide new opportunities for the greater U.K. diabetes community to analyze and personalize their treatment.
With this launch, DarioHealth proves its continued commitment to the U.K. market as it expands market penetration, providing consumers more accessibility to DarioHealth products. Until today, DarioHealth was only available through pharmacies and diabetes educators in the U.K. Now, consumers will have the opportunity to receive personalized diabetes care via an online shopping experience, and be enabled to monitor their health in a more convenient way. DarioHealth will bring its expansive online digital marketing efforts, while having a strong infrastructure and partner in Advance Therapeutics (UK) Ltd., a U.K. wide distributor of specialist medical devices for the treatment of diabetes.
Erez Raphael, Chairman and CEO of DarioHealth, commented on the announcement, "DarioHealth has been operating in the U.K. market for several years now and today's announcement strengthens DarioHealth's commitment to the diabetes community within the U.K. Our U.K. partner, Advanced Therapeutics, has the flexibility to offer customers quick, reliable, and friendly service, which will greatly benefit our customers. Furthermore, they have over 11 years of experience in the diabetes industry which is very important to us, as this demonstrates their true understanding of our customers' needs."
John Hughes, Managing Director of Advanced Therapeutics (UK) Ltd., said of the partnership, "We couldn't be more delighted with today's announcement and we look forward to our continued partnership with DarioHealth. DarioHealth has a highly skilled and professional team and their approach will yield great results. The Dario smart diabetes management system is already well-received and trusted here in the U.K. as an easy-to-use, accurate blood glucose monitor."
DarioHealth is the creator of the acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter that is small enough to fit in one's pocket or purse. Along with the proprietary native smartphone app, consumers can track and monitor their blood glucose levels with test strips in a simple manner, without carrying an additional dedicated device or traditional diabetes kit. This provides people with diabetes an unrivaled method for self-diabetes management.
About Advanced Therapeutics (UK) Ltd.
Advanced Therapeutics (UK) Limited are a U.K. wide distributor of specialist medical devices that meet real clinical needs, simplify therapy and improve quality of life. Advanced Therapeutics (UK) Limited are the exclusive UK distributor for Dario™, a product range by DarioHealth built around a cloud based Diabetes Management System. Dario is designed with convenience, efficiency and results in mind, providing an excellent solution to diabetes management and putting it in the palm of the user. These innovative products all work to improve patient health, provide a flexibility of lifestyle and achieve good clinical outcomes.
Advanced Therapeutics (UK) Ltd. provide high quality training and support to diabetes teams and patients, having the flexibility to be able to offer an efficient, reliable and yet friendly service. The 24 hour technical support is provided by a U.K. based team, with 24 hour clinical support offered where needed. Advanced Therapeutics (UK) Ltd. take pride in their ethos of working within the highest ethical and moral standards. For more information visit http://www.atuk.ltd
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company states that it will bring its expansive digital marketing effort to the U.K., that Advance Therapeutics (UK) Ltd. will greatly benefit the Company's customers and that the Company's professional team and approach will yield great results, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate and Media Contact
DarioHealth Investor Relations Contact
Rob Fink / Brett Maas
+1-646-415-8972 / +1-646-536-7331
Advanced Therapeutics Contact
SOURCE DarioHealth Corp.